Background Tumor budding reflects detachment of single malignant cells or small cell clusters from the main tumor and is increasingly recognized as a morphologic indicator of invasive potential. Tumor-infiltrating lymphocytes represent the host immune response within the tumor microenvironment and provide complementary biological information in breast carcinoma. Objectives To assess intratumoral budding, peritumoral budding, stromal tumor-infiltrating lymphocytes, and intratumoral tumor-infiltrating lymphocytes in invasive breast carcinoma and determine their associations with selected clinicopathological parameters. Methods This hospital-based observational histopathological study included 42 mastectomy specimens. Hematoxylin and eosin-stained sections were examined for tumor-budding hotspots. Intratumoral and peritumoral budding were categorized as high or low using the study-defined threshold of more than four buds across 10 high-power fields. Tumor-infiltrating lymphocytes were assessed morphologically and analyzed using the recorded low and high categories. Estrogen receptor, progesterone receptor, and HER2 results were available for a subset of cases. Associations were assessed using chi-square testing, with statistical significance set at p<0.05. Results High ITB and PTB were each identified in 19/42 cases (45.2%). Both ITB (p=0.0001) and PTB (p=0.0006) showed statistically significant associations with lymph-node metastasis, which was present in 19/42 cases (45.2%). Low iTILs were observed in 34/42 cases (81.0%), while low sTILs were identified in 29/42 cases (69.0%). PTB showed no significant association with iTILs (χ²=0.0905; p=0.763) or sTILs (χ²=0.5631; p=0.453). Associations of tumor budding with age, lymphovascular invasion, histological grade, tumor size, and receptor status were not statistically significant (all p>0.05). Conclusion Tumor budding, particularly its association with nodal metastasis, appears to identify an aggressive histomorphological phenotype in invasive breast carcinoma. The present series did not demonstrate a significant relationship between tumor budding and tumor-infiltrating lymphocyte categories. Recommendations Larger multicentre studies using standardized budding and lymphocyte-scoring systems, survival endpoints, and reproducibility assessment are recommended before routine incorporation into breast carcinoma reporting protocols.
No takes yet. Share an insight, caveat, or question.
Guntaka et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: